Green Fresh Biotechnology Company Limited
Green Fresh Biotechnology Company Limited Fundamental Analysis
Green Fresh Biotechnology Company Limited (1084.HK) shows weak financial fundamentals with a PE ratio of 75.97, profit margin of 1.06%, and ROE of 0.88%. The company generates $0.7B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 29.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1084.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1084.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1084.HK shows balanced valuation metrics.
Growth Score
Moderate1084.HK shows steady but slowing expansion.
Financial Health Score
Excellent1084.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate1084.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 1084.HK Expensive or Cheap?
P/E Ratio
1084.HK trades at 75.97 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1084.HK's PEG of -1.61 indicates potential undervaluation.
Price to Book
The market values Green Fresh Biotechnology Company Limited at 0.65 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 1.17 times EBITDA. This is generally considered low.
How Well Does 1084.HK Make Money?
Net Profit Margin
For every $100 in sales, Green Fresh Biotechnology Company Limited keeps $1.06 as profit after all expenses.
Operating Margin
Core operations generate 4.14 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.88 in profit for every $100 of shareholder equity.
ROA
Green Fresh Biotechnology Company Limited generates $0.45 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Green Fresh Biotechnology Company Limited generates limited operating cash flow of $60.60M, signaling weaker underlying cash strength.
Free Cash Flow
Green Fresh Biotechnology Company Limited produces free cash flow of $28.69M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.03 in free cash annually.
FCF Yield
1084.HK converts 4.83% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
75.97
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.61
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.65
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.81
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.67
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.73
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.009
vs 25 benchmark
ROA
Return on assets percentage
0.005
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How 1084.HK Stacks Against Its Sector Peers
| Metric | 1084.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 75.97 | 22.36 | Worse (Expensive) |
| ROE | 0.88% | 1238.00% | Weak |
| Net Margin | 1.06% | -5096.00% (disorted) | Weak |
| Debt/Equity | 0.67 | 1.23 | Strong (Low Leverage) |
| Current Ratio | 1.73 | 2.47 | Neutral |
| ROA | 0.45% | -191998.00% (disorted) | Weak |
1084.HK outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Green Fresh Biotechnology Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Dividend, Low Volatility
EPS CAGR
N/A
Industry Style: Defensive, Dividend, Low Volatility
FCF CAGR
N/A
Industry Style: Defensive, Dividend, Low Volatility